The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

The European Commission (EC) has granted conditional approval to SpringWorks Therapeutics’ Ezmekly (mirdametinib) to treat ...

The European Commission has approved EZMEKLY (mirdametinib) for treatment of symptomatic, inoperable plexiform neurofibromas ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) ...

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted conditional marketing authorization ...

Merck KGaA said its Ezmekly therapy for people with a rare genetic disorder has received the conditional marketing approval from the European Commission. The pharmaceutical company said Friday that ...

Hard on the heels of a new $575 million partnership with GSK, US biotech SpringWorks Therapeutics has reported phase 3 data at ESMO that sets up regulatory filings for its lead drug nirogacestat ...

The European Commission granted conditional marketing authorization for Ezmekly (mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients ...

Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?

The German pharmaceutical company Merck is in talks to acquire the assets of the American SpringWorks Therapeutics Inc. at a price of $47 per share. This is reported in a press release from Merck. As ...

The German pharmaceutical company Merck KGaA is negotiating the acquisition of the American manufacturer of drugs for the treatment of cancer and rare diseases SpringWorks Therapeutics Inc. This is ...